Belgium's Novadip raises €10M to finish phase 3 bone-repair trial
What's the deal? Novadip Biosciences, a biotech based in Belgium's Brabant region, has raised €10 million to complete the phase 3 trial of its bone-repair treatment. The company is targeting regulatory approval in 2028.
What's the endgame? Novadip is developing a treatment for congenital pseudarthrosis of the tibia in children — a rare condition that impairs bone healing. The fresh capital is earmarked to finish the late-stage clinical trial.
Why now? With the phase 3 study nearing completion, the funding gives Novadip the runway to close out testing and pursue authorisation, which it expects in 2028.
The signal: The round underscores continued investor appetite for late-stage biotech tackling rare paediatric conditions, where regulatory clarity and unmet need can support a path to market.
Read more: lecho.be
Image credit: Generated with Gemini
